A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Platinum Failure
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Atezolizumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms POPLAR
- Sponsors Roche
- 01 Dec 2023 Results assessing the transcriptomic analysis with multiplex immunohistofluorescence (mIHF) on tumor tissue and with proteomic profiling of plasma from patients included in the open-label, randomized phase 2 POPLAR (NCT01903993) and phase 3 OAK trials (NCT02008227), which evaluated atezolizumab versus docetaxel in patients with NSCLC who progressed following platinum-based chemotherapy, published in the Clinical Cancer Research.
- 06 Jun 2023 Results demonstrating the atezolizumab response score (ARS), uses digital pathology features of the shape and size of nuclei in the tumor epithelium to predict response to atezolizumab in patients from POPLAR and OAK trials with non-small cell lung cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 19 Apr 2023 Results from from POPLAR and OAK studies , investigating the role of IDO1 expression in the outcome of NSCLC patients treated with immunotherapy, presented at the 114th Annual Meeting of the American Association for Cancer Research